- Home
- PSNL vs CLVT Comparison
PSNL vs CLVT Comparison
Compare PSNL & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | CLVT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PSNL | CLVT |
|---|---|---|
| Price | $16.60 | $1.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | ★ $12.20 | $3.22 |
| AVG Volume (30 Days) | ★ 3.6M | 3.5M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 68.75 |
| EPS | N/A | ★ N/A |
| Revenue | $69,648,000.00 | ★ $974,345,000.00 |
| Revenue This Year | $15.34 | N/A |
| Revenue Next Year | $41.46 | $2.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.61 |
| 52 Week Low | $4.96 | $1.66 |
| 52 Week High | $18.89 | $4.46 |
Technical Indicators
Market Signals| Indicator | PSNL | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 41.21 |
| Support Level | $7.41 | $1.75 |
| Resistance Level | $18.89 | $2.07 |
| Average True Range (ATR) | 0.88 | 0.13 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 48.43 | 8.00 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.